Insights

Affordability Drive Tevogen aims to reduce the cost of medicines and improve patient access, presenting an opportunity to position technology-enabled procurement optimization, scalable manufacturing partnerships, and value-based pricing discussions with health systems and payers.

Integrated Platform With Tevogen Bio, Tevogen AI, and Tevogen Healthcare Services, there is a potential to upsell cross‑functional solutions such as AI-driven R&D analytics, data interoperability services, and end‑to‑end patient access programs for streamlined drug development and deployment.

Data and Tech Edge A tech stack spanning Snowflake, SQL/NoSQL, Hadoop and cloud tools suggests opportunities for data collaboration, analytics partnerships, and cloud‑based pharmacovigilance, real‑world evidence generation, and supply chain optimization.

Growth Trajectory Revenue range and substantial funding indicate a scale‑up phase with needs in clinical development support, manufacturing capacity planning, regulatory affairs, and strategic partnerships to accelerate market entry and geographic expansion.

Market Positioning Operating in biotechnology with a focus on accessibility positions Tevogen to engage academia, contract manufacturers, and payer organizations for collaboration on cost‑reduction programs, patient access initiatives, and co‑development opportunities.

Similar companies to TEVOGEN

TEVOGEN Tech Stack

TEVOGEN uses 8 technology products and services including SAS, Amazon Web Services, Apache Airflow, and more. Explore TEVOGEN's tech stack below.

TEVOGEN's Email Address Formats

TEVOGEN uses at least 1 email format:
TEVOGEN Email FormatsExamplePercentage
First.Last@tevogen.comJohn.Doe@tevogen.com
100%

Frequently Asked Questions

What is TEVOGEN's stock symbol?

Minus sign iconPlus sign icon
TEVOGEN is a publicly traded company; the company's stock symbol is TVGNW.

What is TEVOGEN's official website and social media links?

Minus sign iconPlus sign icon
TEVOGEN's official website is tevogen.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does TEVOGEN generate?

Minus sign iconPlus sign icon
As of August 2026, TEVOGEN's annual revenue is estimated to be $10M - $25M.

What is TEVOGEN's SIC code and NAICS code?

Minus sign iconPlus sign icon
TEVOGEN's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does TEVOGEN have currently?

Minus sign iconPlus sign icon
As of August 2026, TEVOGEN has approximately 25 employees across 2 continents, including North America and Europe. Key team members include Corporate Identity Lead: W. S., Trade Surveillance And Analytics: A. P. and : D. G. Explore TEVOGEN's employee directory with LeadIQ.

What industry does TEVOGEN belong to?

Minus sign iconPlus sign icon
TEVOGEN operates in the Biotechnology Research industry.

What technology does TEVOGEN use?

Minus sign iconPlus sign icon
TEVOGEN's tech stack includes SAS, Amazon Web Services, Apache Airflow, Salesforce, Shopify, Google Cloud Platform, DocuSign and Heroku.

What is TEVOGEN's email format?

Minus sign iconPlus sign icon
TEVOGEN's email format typically follows the pattern of First.Last@tevogen.com. Find more TEVOGEN email formats with LeadIQ.

How much funding has TEVOGEN raised to date?

Minus sign iconPlus sign icon
As of August 2026, TEVOGEN has raised $120M in funding. The last funding round occurred on May 12, 2026 for $14M.

When was TEVOGEN founded?

Minus sign iconPlus sign icon
TEVOGEN was founded in 2020.
TEVOGEN logo

TEVOGEN

Biotechnology ResearchNew Jersey, United States11-50 Employees

Tevogen Bio is a biotechnology research company based in Warren, New Jersey, that brings together scientists, senior biopharmaceutical leaders, and manufacturing experts to advance global health. Its work centers on immunotherapies built on proprietary cell and gene therapy platforms, with a focus on cancers and viral infections that have high unmet medical need. The firm emphasizes a patient-centric approach and a vision of healthier worlds achieved through equitable access to lifesaving innovations. Its ExacTcell platform represents a core development, aiming at off-the-shelf, genetically unmodified CD8+ T cell therapies for cancer and viral infections. As a relatively small organization, Tevogen Bio participates in industry events and pursues AI- and data-driven research initiatives led by its CIO, Mittul Mehta, who heads Tevogen.AI.

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
Stock Symbol
TVGNW
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2020
Employees
11-50

Section iconFunding & Financials

  • $120M

    TEVOGEN has raised a total of $120M of funding over 12 rounds. Their latest funding round was raised on May 12, 2026 in the amount of $14M as a Post IPO Equity.

  • $10M - $25M

    TEVOGEN's revenue is estimated to be in the range of $10M - $25M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.